Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
BioAegis Therapeutics General Information
BioAegis Therapeutics’ lead asset—recombinant human plasma gelsolin—is in a global Phase 2 trial for moderate-to-severe ARDS. The study involves over 600 patients across multiple countries and aims to demonstrate efficacy in improving survival without organ failure at Day 28. The company’s approach has shown promise as a non-immunosuppressive anti-inflammatory therapy that restores innate immune balance and may address high unmet needs in severe inflammatory conditions. Early results have supported safety and mechanistic rationale; pivotal efficacy data are pending from the ongoing trial.[6][8]
Contact Information
Primary Industry
Biotech
Corporate Office
North Brunswick, New Jersey
United States
United States
Drug Pipeline
recombinant human plasma gelsolin
Phase 2Key Partnerships
BARDA – $20 million contract to support ARDS clinical development of rhu-pGSN [6][10]
BioAegis Therapeutics Funding
No funding data available
To view BioAegis Therapeutics's complete valuation and funding history, request access »